The TOPCAT trial also reported higher values of Gal-3 in patients with T2DM and HFpEF (22 ng/mL) in comparison with T2DM patients without HF (20 ng/L, p < 0.001) [56]. This evidence concerns the gene LGALS3 and hydrops fetalis.